Genentech Sends Raptiva “Dear Doctor” Letter To Dermatologists, Nurses

Letter addresses new warning in efalizumab labeling on immune-mediated hemolytic anemia. Two cases of hemolytic anemia were observed in clinical trials and two additional cases were observed in postmarketing adverse event monitoring.